Home » Newsletters » BioWorld Science

BioWorld Science

April 4, 2001

View Archived Issues

AstraZeneca does not exercise option for TAPET-CPG2

Vernalis makes significant progress during past year

MabCampath recommended for approval in the E.U.

Sepracor submits sNDA to FDA for pediatric use of Xopenex

SBL Vaccin to distribute, market Aventis Pasteur vaccines in Sweden

NZ-1001 restores normal skeletal muscle function in mouse model

FDA extends review period for Xyrem

Telik moves TLK-286 to phase II

ID Biomedical begins purchase of Intellivax

Travatan launch quickly follows first approval in U.S.

MEDI-507 enters phase II evaluation in patients with psoriasis

Ligand updates Targretin developments in the E.U.

Nonopioid DOP agonists presented at ACS meeting by Pfizer group

Canadian regulatory approval obtained for new HIV protease inhibitor combination

Phase II studies commence for Titan's gallium formulation

Twinstrand takes a novel approach to cancer treatment, as reported at AACR meeting

Drug candidate for diabetic complications emerges from R&D at Dynamis

Imidazoline-based alpha1A-selective compounds from GSK targeted for urinary incontinence

Two series of antitumor agents prepared and tested at Lafon

New matrix metalloproteinase inhibitors and potential uses claimed by former Warner-Lambert

Spirocyclic sigma receptor ligands in the Sepracor pipeline

Southern Research Institute presents preparation and uses of new compounds derived from naltrexone

Cell adhesion inhibitors identified by Merck group

Selective Y5 receptor antagonists characterized at GSK, useful as pharmacological tools

Kikkoman discloses new series of selective alpha-glucosidase inhibitors

New PKC activators useful for ocular hypertension, glaucoma, etc.

Putative TPO receptor modulator discovered by Receptron scientists enters phase I

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...